PMID- 31351424
OWN - NLM
STAT- MEDLINE
DCOM- 20200218
LR  - 20200218
IS  - 1950-6007 (Electronic)
IS  - 0753-3322 (Linking)
VI  - 118
DP  - 2019 Oct
TI  - LncRNA RGMB-AS1 promotes laryngeal squamous cell carcinoma cells progression via 
      sponging miR-22/NLRP3 axis.
PG  - 109222
LID - S0753-3322(19)32697-6 [pii]
LID - 10.1016/j.biopha.2019.109222 [doi]
AB  - Long non-coding RNA RGMB-AS1 (lncRNA RGMB-AS1) was reported to play important 
      roles in human cancer progression. However, the roles of lncRNA RGMB-AS1 in 
      laryngeal squamous cell carcinoma (LSCC) remain unclear. In our research, lncRNA 
      RGMB-AS1 was shown to be upregulated in LSCC tissues. High RGMB-AS1 expression 
      was closely associated with advanced clinical features and poor prognosis. 
      Silencing of lncRNA RGMB-AS1 suppressed LSCC cells proliferation and invasion in 
      vitro and inhibited tumor growth in vivo. In mechanism, lncRNA RGMB-AS1 could 
      sponge miR-22 to upregulate the expression of NLRP3. Additionally, we verified 
      that the suppression of LSCC progression induced by lncRNA RGMB-AS1 reduction 
      required the activity of miR-22. Altogether, these findings elucidated that 
      lncRNA RGMB-AS1 could exert as an oncogenic factor through modulating 
      miR-22/NLRP3 pathway, suggesting a potential novel target for the treatment of 
      LSCC.
CI  - Copyright (c) 2019 The Authors. Published by Elsevier Masson SAS.. All rights 
      reserved.
FAU - Xu, Zhenxing
AU  - Xu Z
AD  - Department of Otorhinolaryngology, The First Affiliated Hospital, and College of 
      Clinical Medicine of Henan University of Science and Technology, Luoyang, 471003, 
      China.
FAU - Xi, Kai
AU  - Xi K
AD  - Department of Otorhinolaryngology, The First Affiliated Hospital, and College of 
      Clinical Medicine of Henan University of Science and Technology, Luoyang, 471003, 
      China. Electronic address: xikaikxdoc@163.com.
LA  - eng
PT  - Journal Article
DEP - 20190724
PL  - France
TA  - Biomed Pharmacother
JT  - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
JID - 8213295
RN  - 0 (MIRN22 microRNA, human)
RN  - 0 (MicroRNAs)
RN  - 0 (NLR Family, Pyrin Domain-Containing 3 Protein)
RN  - 0 (NLRP3 protein, human)
RN  - 0 (RNA, Long Noncoding)
RN  - 0 (long noncoding RNA RGMB-AS1, human)
SB  - IM
MH  - Base Sequence
MH  - Carcinoma, Squamous Cell/*genetics
MH  - Cell Line, Tumor
MH  - Cell Proliferation/genetics
MH  - *Disease Progression
MH  - Down-Regulation/genetics
MH  - Gene Expression Regulation, Neoplastic
MH  - Gene Silencing
MH  - Humans
MH  - Laryngeal Neoplasms/*genetics/*pathology
MH  - MicroRNAs/genetics/*metabolism
MH  - NLR Family, Pyrin Domain-Containing 3 Protein/*metabolism
MH  - Neoplasm Invasiveness
MH  - RNA, Long Noncoding/genetics/*metabolism
OTO - NOTNLM
OT  - Laryngeal squamous cell carcinoma
OT  - NLRP3
OT  - lncRNA RGMB-AS1
OT  - miR-22
EDAT- 2019/07/28 06:00
MHDA- 2020/02/19 06:00
CRDT- 2019/07/28 06:00
PHST- 2019/06/06 00:00 [received]
PHST- 2019/07/09 00:00 [revised]
PHST- 2019/07/10 00:00 [accepted]
PHST- 2019/07/28 06:00 [pubmed]
PHST- 2020/02/19 06:00 [medline]
PHST- 2019/07/28 06:00 [entrez]
AID - S0753-3322(19)32697-6 [pii]
AID - 10.1016/j.biopha.2019.109222 [doi]
PST - ppublish
SO  - Biomed Pharmacother. 2019 Oct;118:109222. doi: 10.1016/j.biopha.2019.109222. Epub 
      2019 Jul 24.